substantial holder - professional accumulator, page-10

FOUND THIS INTERESTING HHL March 2014

http://www.hunterhall.com.au/pdf/MPR/Archives/2014/03_MPR_GDG_Mar2014.pdf

The Company’s largest position, Australian liver cancer treatment company Sirtex Medical was the largest positive contributor to portfolio performance. In early April, the company announced its 39th consecutive quarter of dose sales growth, up 18.2% for the quarter to 31st March 2014. Dose sales grew in all regions with the Americas up 25.8%, Europe up 3.6% and Asia Pacific up 8.6%.

Australian Alzheimer’s treatment developer Prana Biotechnology was the largest detractor from portfolio performance for the month. The company’s experimental drug for Alzheimer’s disease failed to help patients in a trial. Treatment with the drug led to no improvement in brain metabolic activity, cognition and function. We sold 72% of our investment before the trial results were released in order to lock in profit.

SO RATHER THAN SELLING ACL, THEY ARE BUYING, NO LOCKING IN PROFITS BECAUSE THE AVERAGE BUY IS 0.59 WHAT IT OWES THEM.
THEY CONTINUE TO BUY

NO LOCKING IN PROFITS BEFORE THE RESULTS, NO THEY ARE BUYING ACL. LOOKING FORWARD TO THE RESULTS.

BIG BUYS AT 0.55 BUT WE SIT AT 0.50 GO FIGURE THAT ONE OUT

IMHO